AI Insight
This commentary discusses treatment approaches for primary CNS lymphoma (PCNSL), highlighting two established principles: induction therapy should use high-dose methotrexate-based polychemotherapy to achieve tumor response, and post-induction consolidation therapy is necessary to prevent relapse. The article notes that while these core principles have broad consensus, significant practice variations remain regarding which chemotherapy agents to combine with methotrexate and the optimal consolidation strategy, with the title suggesting autologous stem-cell transplantation should become the standard consolidation approach.
Why it matters
Establishing a standardized consolidation strategy for PCNSL could improve patient outcomes by reducing relapse rates and providing clearer treatment guidelines for oncologists. The recommendation for autologous stem-cell transplantation as standard practice may shift clinical protocols and treatment decision-making for this rare and aggressive brain cancer.
Understand the Science
There are core principles that command broad consensus in the initial treatment of patients with primary CNS lymphoma (PCNSL). First, induction should consist of a high-dose methotrexate-based polychemotherapy regimen to elicit tumour response. Second, post-induction therapy following response is needed to prevent relapse.1 Beyond these principles, key practice differences persist without consensus on which chemotherapy agents to combine with methotrexate and the optimal post-induction consolidation strategy.